BIOMARK RETAINS QUESTRADE, INC. TO PROVIDE MARKET MAKING SERVICES

questrade

Vancouver, British Columbia – (December 7th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that it has retained Questrade, Inc. (“Questrade”) to provide market-making services in accordance with CSE guidelines. The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either […]

Richmond company looking for ‘holy grail’ in COVID-19 testing

holy-grail-in-covid-19-testing

A rapid COVID-19 saliva test could be used wherever crowds gatherMaria Rantanen / Richmond News A Richmond biomedical company is in a race to create a rapid, cheap and portable saliva test for COVID-19 to help open up the economy and give people more freedom to move. Rashid Bux — president and CEO of BioMark Diagnostics […]

BIOMARK TEAM INVITED FOR FULL APPLICATION FOR SPARKS GRANT COMPETITION

biomark team invited for full application for sparks grant competition

Vancouver, British Columbia – (September 14th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This […]

BIOMARK TEAM SECURES HEALTH CANADA LETTER OF NO OBJECTION FOR ITS GLIOBLASTOMA CLINICAL TRIAL

biomark team secures health canada letter of no objection for its blioblastoma clinical trial

Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company […]

BioMark Diagnostics Expands Research Development in Quebec

biomark expands research and development in quebec

Vancouver, British Columbia – (August 13th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP,  an incubator-accelerator dedicated to tech businesses growth and mentorship. […]

BioMark’s Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing

biostream announces partnership with Qatar University for covid 19 testing

The Company will leverage Raman spectroscopy and Machine Learning as part of its diagnostics Vancouver, British Columbia – (July 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that its affiliated company, Bio-Stream Diagnostics Inc.,  will be working with University of Qatar’s Dr. Somaya Al-Maadeed in the development of […]

BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”

biomark receives full registered trademark from USPTO

Vancouver, British Columbia – (July 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”.  The term “BioMark” was selected by the company in reference to […]

BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer

biomark announces peer reviewed publication on detection of cancer

Vancouver, British Columbia – (June 23 , 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer […]